Objectives: Lung cancer is the leading cause of cancer-related mortality in both men and women worldwide. Small cell lung cancer (SCLC) represents 15-20 % of all lung cancers. The aim of this study was to evaluate the clinical features of small cell lung cancer (NSCLC) cases that were diagnosed in our clinic. Methods: The patients who were diagnosed as SCLC in our clinic were comprised the study group. The files and records of the study group were retrospectively reviewed to identify patients. The study group included 64 patients (59male, 5 female). Results: The mean age was 57.5 ±8.1 years. All patients were current smokers ( 50,3 pack-year). The most frequent symptoms on admission were chest pain, cough and weight loss. The most common radiologic finding was a hilar solid mass and hilar lymphadenopathies. The diagnosis was established by histopathologic examination of biopsy specimens obtained by various means, in which bronchoscopy was the sole means of diagnosis in 92,2 % of the patients. The stages of SCLC were limited disease in 26(29,7 %) and extensive disease in 38 (59,3%) patients. Metastasis was most frequently to the liver followed by bone and brain. Five (7,8%) patient had complete response (CR). forty nine (76,5%) patients had partial response. The median survival was 309 days, 210 days and 270 days for LS, ES and overall patients, respectively. Conclusions: In conclusion, demographic and clinical features of the patients were similar with the literature. Due to the high rates of extensive disease, the median survival rates and responses were lower than the previous series.
1. Brambilla E, Travis WD, Colby TV, Corrin B, Shimosato Y. The new World Health Organization classification of lung tumors. ERJ. 2001; 18:105968.
2. Jett JR, Schild SE, Kesler KA, Kalemkerian GP. Treatment of small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 Suppl):e400S-19S.
3. Kalemkerian GP, Akerley W, Bogner P, et al. Small cell lung cancer. J Natl Compr Canc Netw. 2011;9(10):1086- 113.
4. Shepherd FA, Crowley J, Van Houtte P, et al. The International Association for the Study of Lung Cancer lung cancer staging project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer. J Thorac Oncol. 2007;2(12):1067-77.
5. Schneider BJ, Saxena A, Downey RJ. Surgery for earlystage small cell lung cancer. J Natl Compr Netw. 2011;9(10):1132-9.
6. Bharti MK, Chauhan A, Kaushal V et al.Characterıstıcs, Treatment Patterns And Outcomes Of Patıents Wıth Small Cell Lung Cancer - A Retrospectıve Analysıs. IJPSR, 2011; Vol. 2(8): 2206-2210.
7. Osterlind K, Ihde DC, Ettinger DS, Gralla RJ, Karrer K, Krauss S, et al. Staging and prognostic factors in small cell carcinoma of the lung. Cancer Treat Rep 1983;67(1):3-9.
8. Maestu I, Pastor M, Gómez-Codina J, Aparicio J, Oltra A, Herranz C, et al. Pretreatment prognostic factors for survival in small-cell lung cancer: a new prognostic index and validation of three known prognostic indices on 341 patients. Ann Oncol 1997;8(6):547-53.
9. Tsao AS, Liu D, Lee JJ, Spitz M, Hong WK. Smoking affects treatment outcome in patients with advanced nonsmall cell lung cancer. Cancer 2006;106(11):2428-36.
10. Wistuba II, Lam S, Behrens C, Virmani AK, Fong KM, LeRiche J, et al. Molecular damage in the bronchial epithelium of current and former smokers. J Natl Cancer Inst 1997;89(18):1366-73.
11. Mao L, Lee JS, Kurie JM, Fan YH, Lippman SM, Lee JJ, et al. Clonal genetic alterations in the lungs of current and former smokers. J Natl Cancer Inst 1997;89(12):857-62.
12. Johnston RN, Smith DH. Symptoms and survival in lung cancer. Lancet 1968;2:588-91.
13. Senior RM, Adamson JS. Survival in patients with lung cancer. An appraisal of Feinstein's symptom classification. Arch Intern Med 1970;125:975-80.
14. Johnson DV, Blanke CD. Small cell lung cancer: Diagnosis, treatment and natural history.In Fishman AP,Eds. Pulmonary diseases and disorders. 3rd Ed.New York: McGraw-Hill Companies ; 1998. p.1819-1831.
15. Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small lung cancer. N Engl J Med 2002;346:8591.
16. Hanna N, Bunn Jr PA, Langer C, et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 2006;24:203843.
17. Sheperd FA, Crowley J, van Houte J, et al. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer. J Thorac Oncol 2007;2:1067 77.
18. Fizazi K, Cojean I, Pignon JP, Rixe O, Gatineau M, Hadef S, et al . Normal Serum Neuron Specific Enolase (NSE) Value after the First Cycle of Chemotherapy. Cancer 1998;82:1049-55.
19. Tatlisöz H,Erkan L, Fındık S et al.Clinical features and outcomes of small cell lung cancer cases from northern Turkey.Turkish Respiratory Journal 2000;2:25-29.
20. Sonmez B, Ay B, Eldemir YÖ, Altınbas M.Demographic and other characteristics of small cell lung carcinoma cases:retrospective analysis, single center study. Türk Onkoloji Dergisi 2012;27(3):107-110.